Tvardi Therapeutics, Inc. (TVRD) stock
TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.18+0.02 (+2.16%)
Close on Nov 13, 2026Market cap $15.74MP/E –Yield 0.00%
Tvardi Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Tvardi Therapeutics's operating margin for the twelve months ending Mar 31, 2025 was -370.0%. For fiscal 2024 it was -393.8%, against -579.4% the year before. The highest annual figure on record is 4.0% in fiscal 2020.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -393.8% | +185.6 |
| FY2023 | Dec 31, 2023 | -579.4% | −370.4 |
| FY2022 | Dec 31, 2022 | -209.1% | +177.8 |
| FY2021 | Dec 31, 2021 | -386.8% | −390.8 |
| FY2020 | Dec 31, 2020 | 4.0% | +565.6 |
| FY2019 | Dec 31, 2019 | -561.6% | +12.9 |
| FY2018 | Dec 31, 2018 | -574.5% | +5955.1 |
| FY2017 | Dec 31, 2017 | -6529.6% | +61377.3 |
| FY2016 | Dec 31, 2016 | -67907.0% | −67244.7 |
| FY2015 | Dec 31, 2015 | -662.3% | −93.5 |
| FY2014 | Dec 31, 2014 | -568.8% | −566.9 |
| FY2013 | Dec 31, 2013 | -2.0% | +522.1 |
| FY2012 | Dec 31, 2012 | -524.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | -169.5% | +1220.0 |
| Q4 FY2024 | Dec 31, 2024 | -742.4% | +343.0 |
| Q3 FY2024 | Sep 30, 2024 | -222.1% | +371.8 |
| Q2 FY2024 | Jun 30, 2024 | -724.6% | −258.2 |
| Q1 FY2024 | Mar 31, 2024 | -1389.5% | −941.0 |
| Q4 FY2023 | Dec 31, 2023 | -1085.5% | −125.4 |
| Q3 FY2023 | Sep 30, 2023 | -593.9% | −373.4 |
| Q2 FY2023 | Jun 30, 2023 | -466.5% | −447.0 |
| Q1 FY2023 | Mar 31, 2023 | -448.5% | +134.2 |
| Q4 FY2022 | Dec 31, 2022 | -960.0% | +3123.0 |
| Q3 FY2022 | Sep 30, 2022 | -220.5% | −215.0 |
| Q2 FY2022 | Jun 30, 2022 | -19.4% | +1198.2 |
| Q1 FY2022 | Mar 31, 2022 | -582.7% | −652.5 |
| Q4 FY2021 | Dec 31, 2021 | -4083.1% | −3899.4 |
| Q3 FY2021 | Sep 30, 2021 | -5.5% | +453.9 |
| Q1 FY2021 | Mar 31, 2021 | -1217.6% | −846.9 |
| Q4 FY2020 | Dec 31, 2020 | 69.8% | +734.2 |
| Q3 FY2020 | Sep 30, 2020 | -183.7% | +411.5 |
| Q2 FY2020 | Jun 30, 2020 | -459.4% | +4.1 |
| Q1 FY2020 | Mar 31, 2020 | -370.7% | +157.2 |
| Q4 FY2019 | Dec 31, 2019 | -664.4% | −267.2 |
| Q3 FY2019 | Sep 30, 2019 | -595.2% | −190.9 |
| Q2 FY2019 | Jun 30, 2019 | -463.6% | +156.2 |
| Q1 FY2019 | Mar 31, 2019 | -527.9% | +1922.7 |
| Q4 FY2018 | Dec 31, 2018 | -397.2% | – |
| Q3 FY2018 | Sep 30, 2018 | -404.3% | – |
| Q2 FY2018 | Jun 30, 2018 | -619.8% | – |
| Q1 FY2017 | Mar 31, 2017 | -2450.6% | – |
See a number that looks wrong?